Tumor Hypoxia in Cancer Therapy
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Self-citationHypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
(1999) · PubMed · Cited by 2,204
Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. A. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-312-638 · Cited by 2,158
Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
(1996) · PubMed · Cited by 1,188
Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors
Moeller, B. J., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00115-1 · Cited by 996
Nordsmark, M., Bentzen, S. M., Rudat, V., Brizel, D., Lartigau, E., Stadler, P., Becker, A., Adam, M., Molls, M., Dunst, J., et al. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.06.038 · Cited by 953
Nordsmark, M., Overgaard, M., & Overgaard, J. (1996) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(96)91811-3 · Cited by 942
(2002) · PubMed · Cited by 840
Riballo, E., Kühne, M., Rief, N., Doherty, A., Smith, G. C. M., Recio, M.-J., Reis, C., Dahm, K., Fricke, A., Krempler, A., et al. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.10.029 · Cited by 837
Radiobiology for the Radiologist
Fowler, J. F., & Hall, E. J. (1988) · Radiation Research · doi:10.2307/3577489 · Cited by 785
Tannock, I. F. (1968) · British Journal of Cancer · doi:10.1038/bjc.1968.34 · Cited by 763
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., & Giannakakou, P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00077-1 · Cited by 730
HIF-1 as a target for drug development
Giaccia, A., Siim, B. G., & Johnson, R. S. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1199 · Cited by 631
Toso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614
XBP1 Is Essential for Survival under Hypoxic Conditions and Is Required for Tumor Growth
Romero-Ramirez, L., Cao, H., Nelson, D., Hammond, E., Lee, A.-H., Yoshida, H., Mori, K., Glimcher, L. H., Denko, N. C., Giaccia, A. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1606 · Cited by 570
Teicher, B. A., Lazo, J. S., & Sartorelli, A. C. (1981) · PubMed · Cited by 555
Radiobiology for the Radiologist
Malamud, H. (1995) · Clinical Nuclear Medicine · doi:10.1097/00003072-199501000-00029 · Cited by 546
Tumor-targeted Salmonella as a novel anticancer vector.
Pawelek, J. M., Low, K. B., & Bermudes, D. G. (1997) · PubMed · Cited by 527
Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation
Brown, J. M. (1979) · The British Journal of Radiology · doi:10.1259/0007-1285-52-620-650 · Cited by 526
Self-citationSuppression of tumor growth through disruption of hypoxia-inducible transcription
Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G., & Livingston, D. M. (2000) · Nature Medicine · doi:10.1038/82146 · Cited by 501
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.009 · Cited by 480
YC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1
Yeo, E.-J., Chun, Y.-S., Cho, Y.-S., Kim, J., Lee, J.-C., Kim, M.-S., & Park, J.-W. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.7.516 · Cited by 476
Tannock, I. F., Hill, R. P., & Carey, R. W. (1989) · Plastic and Reconstructive surgery · doi:10.1097/00006534-198905000-00037 · Cited by 473
Hypoxic gene expression and metastasis
Le, Q.-T., Denko, N. C., & Giaccia, A. J. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031768.89246.d7 · Cited by 468
(2002) · PubMed · Cited by 457
Kimura, H., Braun, R. D., Ong, E. T., Hsu, R., Secomb, T. W., Papahadjopoulos, D., Hong, K., & Dewhirst, M. W. (1996) · PubMed · Cited by 425
Tumor hypoxia: its impact on cancer therapy
Moulder, J. E., & Rockwell, S. (1987) · Cancer and Metastasis Reviews · doi:10.1007/bf00055376 · Cited by 414
SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K., & Lee, W. W. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90267-1 · Cited by 402
Self-citationWachsberger, P. R., Burd, R., & Dicker, A. P. (2003) · PubMed · Cited by 394
Mabjeesh, N. J., Post, D. E., Willard, M. T., Kaur, B., Meir, E. G. V., Simons, J. W., & Zhong, H. (2002) · PubMed · Cited by 343
Wouters, B. G., & Brown, J. M. (1997) · Radiation Research · doi:10.2307/3579620 · Cited by 341
Self-citationTopoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1
Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3139 · Cited by 301
The Phenomenon of Reoxygenation and Its Implications for Fractionated Radiotherapy
Kallman, R. F. (1972) · Radiology · doi:10.1148/105.1.135 · Cited by 294
Wartenberg, M., Ling, F. C., Müschen, M., Klein, F., Acker, H., Gassmann, M., Petrat, K., Pütz, V., Hescheler, J., & Sauer, H. (2003) · The FASEB Journal · doi:10.1096/fj.02-0358fje · Cited by 287
von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L. O., Clark, P., Talbot, D., Rey, A., Butler, T. W., Hirsh, V., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1351 · Cited by 285
Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives
Greco, O., & Dachs, G. U. (2001) · Journal of Cellular Physiology · doi:10.1002/1097-4652(2001)9999:9999<::aid-jcp1060>3.0.co;2-h · Cited by 273
Malmgren, R. A., & Flanigan, C. (1955) · PubMed · Cited by 263
Acute hypoxia in tumors: Implications for modifiers of radiation effects
Chaplin, D. J., Durand, R. E., & Olive, P. L. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90153-7 · Cited by 263
Rischin, D., Peters, L., Fisher, R., Macann, A., Denham, J., Poulsen, M., Jackson, M., Kenny, L., Penniment, M., Corry, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.072 · Cited by 253
Tumor Microenvironment and the Response to Anticancer Therapy
Brown, J. M. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.5.157 · Cited by 232
Self-citationThe bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—I
Anlezark, G. M., Melton, R. G., Sherwood, R. F., Coles, B., Friedlos, F., & Knox, R. J. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90671-5 · Cited by 214
Involvement of Hypoxia-Inducible Factor 1 in Human Cancer.
SEMENZA, G. L. (2002) · Internal Medicine · doi:10.2169/internalmedicine.41.79 · Cited by 208
The macrophage – a novel system to deliver gene therapy to pathological hypoxia
Griffiths, L., Binley, K., Iqball, S., Kan, O., Maxwell, P., Ratcliffe, P., Lewis, C., Harris, A., Kingsman, S., & Naylor, S. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301058 · Cited by 206
Bridgewater, J. A., Springer, C. J., Knox, R. J., Minton, N. P., Michael, N. P., & Collins, M. K. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00436-x · Cited by 205
Liu, S.-C., Minton, N., Giaccia, A., & Brown, J. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301659 · Cited by 194
Self-citationMinton, N. P. (2003) · Nature Reviews Microbiology · doi:10.1038/nrmicro777 · Cited by 192
Conventional cancer therapy: promise broken or promise delayed?
Tannock, I. F. (1998) · The Lancet · doi:10.1016/s0140-6736(98)90327-0 · Cited by 191
Rapisarda, A., Zalek, J., Hollingshead, M., Braunschweig, T., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Hewitt, S. M., Shoemaker, R. H., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2116 · Cited by 187
Brown, J. M., & Lemmon, M. J. (1990) · PubMed · Cited by 181
Self-citationAQ4N: a new approach to hypoxia-activated cancer chemotherapy
Patterson, L. H., & McKeown, S. R. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1564 · Cited by 178
Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment
Lemmon, M., van Zijl, P., Fox, M., Mauchline, M., Giaccia, A., Minton, N., & Brown, J. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300468 · Cited by 174
Self-citationTrinh, Q. T., Austin, E. A., Murray, D. M., Knick, V. C., & Huber, B. E. (1995) · PubMed · Cited by 172
Fox, M. E., Lemmon, M. J., Mauchline, M. L., Davis, T. O., Giaccia, A. J., Minton, N. P., & Brown, J. M. (1996) · PubMed · Cited by 170
Self-citationBurke, B., Tang, N., Corke, K. P., Tazzyman, D., Ameri, K., Wells, M., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1029 · Cited by 169
Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy
Melillo, G. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0235 · Cited by 166
Knox, R. J., Friedlos, F., Jarman, M., & Roberts, J. J. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90335-8 · Cited by 165
Sun, X., Kanwar, J. R., Leung, E. Y., Lehnert, K., Wang, D., & Krissansen, G. W. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301388 · Cited by 160
Hicks, K. O., Pruijn, F. B., Secomb, T. W., Hay, M. P., Hsu, R., Brown, J. M., Denny, W. A., Dewhirst, M. W., & Wilson, W. R. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj306 · Cited by 152
Self-citationHigh-Pressure Oxygen and Radiotherapy
Churchill‐Davidson, I. (1959) · Nature · doi:10.1038/184094b0 · Cited by 149
Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin.
Dorie, M. J., & Brown, J. M. (1993) · PubMed · Cited by 149
Self-citationPatterson, L. H. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00689805 · Cited by 146
Knox, R. J., Boland, M. P., Friedlos, F., Coles, B., Southan, C., & Roberts, J. J. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90336-x · Cited by 146
Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1
Williams, K. J., Telfer, B. A., Xenaki, D., Sheridan, M. T., Desbaillets, I., Peters, H., Honess, D. J., Harris, A. L., Dachs, G. U., van der Kogel, A., et al. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.01.009 · Cited by 143
Beiträge zur Biologie der Strahlenwirkung
Holthusen, H. (1921) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/bf01722061 · Cited by 142
MOESE, J. R., & MOESE, G. (1964) · PubMed · Cited by 141
Chung-Faye, G., Palmer, D. H., Anderson, D., Clark, J., Downes, M., Baddeley, J., Hussain, S. A., Murray, P. I., Searle, P. F., Seymour, L. W., et al. (2001) · PubMed · Cited by 133
Lanzen, J., Braun, R. D., Klitzman, B., Brizel, D., Secomb, T. W., & Dewhirst, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-03-2958 · Cited by 133
Cobb, L., Connors, T. A., Elson, L. A., Khan, A. H., Mitchley, B. C. V., Ross, W. C. J., & Whisson, M. E. (1969) · Biochemical Pharmacology · doi:10.1016/0006-2952(69)90267-6 · Cited by 133
Brown, J. M. (1975) · Radiation Research · doi:10.2307/3574253 · Cited by 128
Self-citationTumour Cytochrome P450 and Drug Activation
Patterson, L. H., & Murray, G. I. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023394502 · Cited by 126
The influence of microenvironmental factors during cancer therapy.
Durand, R. E. (1994) · PubMed · Cited by 111
Carey, R. W., Holland, J. F., Whang, H. Y., Neter, E., & Bryant, B. (1967) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(67)90060-6 · Cited by 104
Hypoxia-mediated tumour targeting
Binley, K. E., Askham, Z., Martin, L. G., Spearman, H., Day, D. M., Kingsman, S. M., & Naylor, S. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301944 · Cited by 98
Shibata, T., Akiyama, N., Noda, M., Sasai, K., & Hiraoka, M. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00298-3 · Cited by 94
The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium
Heppner, F. L., & M�se, J. R. (1978) · Acta Neurochirurgica · doi:10.1007/bf01406639 · Cited by 90
Patterson, L. H. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120005659 · Cited by 86
(2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1163 · Cited by 81
ONCOLYSIS BY CLOSTRIDIA. V. TRANSPLANTED TUMORS OF THE HAMSTER.
Engelbart, K., & Gericke, D. (1964) · PubMed · Cited by 81
ONCOLYSIS BY CLOSTRIDIA. III. EFFECTS OF CLOSTRIDIA AND CHEMOTHERAPEUTIC AGENTS ON RODENT TUMORS.
Thiele, E. H., Arison, R. N., & Boxer, G. E. (1964) · PubMed · Cited by 81
Koch, C. J., Stobbe, C. C., & Bump, E. A. (1984) · PubMed · Cited by 80
Martin, J. E., Stribbling, S. M., Poon, G. K., Beǵent, R. H. J., Napier, M., Sharma, S. K., & Springer, C. J. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050646 · Cited by 80
Hypoxia-Inducible Regulation of a Prodrug-Activating Enzyme for Tumor-Specific Gene Therapy
Shibata, T., Giaccia, A. J., & Brown, J. M. (2002) · Neoplasia · doi:10.1038/sj.neo.7900189 · Cited by 79
Self-citationWilson, W. R., Pullen, S. M., Hogg, A. E., Helsby, N. A., Hicks, K. O., & Denny, W. A. (2002) · PubMed · Cited by 78
Kovacs, M. S., Hocking, D. J., Evans, J., Siim, B. G., Wouters, B. G., & Brown, J. M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690492 · Cited by 76
Self-citationRadiosensitization of C3H Mouse Mammary Tumours by a 2-Nitroimidazole Drug
SHELDON, P. W., Foster, J. L., & Fowler, J. F. (1974) · British Journal of Cancer · doi:10.1038/bjc.1974.235 · Cited by 67
Patterson, A. V., Williams, K. J., Cowen, R. L., Jaffar, M., Telfer, B. A., Saunders, M. P., Airley, R. E., Honess, D. J., van der Kogel, A. J., Wolf, C. R., et al. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301702 · Cited by 64
Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N
McCarthy, H. O., Yakkundi, A., McErlane, V., Hughes, C., Keilty, G. W., Murray, M., Patterson, L. H., Hirst, D. G., McKEOWN, S. R., & Robson, T. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700522 · Cited by 64
Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes.
Hill, S. A., Pigott, K., Saunders, M. I., Powell, M. E. B., Arnold, S., Obeid, A., Ward, G., Leahy, M. J., Hoskin, P., & Chaplin, D. J. (1996) · Europe PMC (PubMed Central) · Cited by 63
Hill, S. A., B.Sc., D. R. C., Vojnovic, B., & Chaplin, D. J. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00892-4 · Cited by 61
Does hyperbaric oxygen have a future in radiation therapy?
Henk, J. M. (1981) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(81)90173-5 · Cited by 54
Onkolyseversuche mit apathogenen, anaeroben Sporenbildnern am Ehrlich-Tumor der Maus
M�se, J. R., & M�se, G. (1959) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00531349 · Cited by 47
The potential benefit from a perfect radiosensitizer and its dependence on reoxygenation
Denekamp, J., & Joiner, M. C. (1982) · British Journal of Radiology · doi:10.1259/0007-1285-55-657-657 · Cited by 33
Oxygen dependence of the cytotoxicity of the enediyne anti-tumour antibiotic esperamicin A1.
Batchelder, R. M., Wilson, W. R., Hay, M. P., & Denny, W. A. (1996) · Europe PMC (PubMed Central) · Cited by 16
(1987) · PubMed
Cited by
The impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365
“Hodgkiss and colleagues in the late 1980s demonstrated that the oxygen effect required O 2 to be present at the exact time of radiation, leading to the oxygen fixation hypothesi”
BackgroundDNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Huang, R.-X., & Zhou, P.-K. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,198
Diffuse optics for tissue monitoring and tomography
Durduran, T., Choe, R., Baker, W. B., & Yodh, A. G. (2010) · Reports on Progress in Physics · doi:10.1088/0034-4885/73/7/076701 · Cited by 1,161
Iron Oxide Based Nanoparticles for Multimodal Imaging and Magnetoresponsive Therapy
Lee, N., Yoo, D., Ling, D., Cho, M. H., Hyeon, T., & Cheon, J. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00112 · Cited by 1,005
Cancer nanomedicine for combination cancer immunotherapy
Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 940
Metadata
- Authors
- Brown, J. M.
- Venue
- Methods in Enzymology
- Publisher
- Elsevier
- Published
- 2007
- Volume
- 435
- Pages
- 295-321
- ISSN
- 0076-6879 (ISSN-L)
- OpenAlex
- W2150437708
- Cited by
- 359
- References
- 98
- FWCI
- 15.92
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.